An observational study in Sleep Apnea, Obstructive, sponsored by Royal Free Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-24.
Sponsored by Royal Free Hospital NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Sleep Apnea, Obstructive · United Kingdom.
Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 28 observational ones that give a count, is one of 5 that started in 2022, is one of 28 observational ones, reaches primary completion later than 1 of the 12 other live ones, and was the 44th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →9 of the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:
Virginia Hawkins · Sites in United Kingdom
Ages 18+
Inspire Medical Systems, Inc. · Sites in United Kingdom, Austria, Belgium and 4 more countries
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Children's Health Ireland · Sites in United Kingdom, Ireland
Ages 6 mo–16 yrs
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 21 days–35 days
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 58 across the 26 interventional studies, 102 across the 28 observational. Of the 36 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
Royal Free Hospital NHS Foundation Trust is the lead sponsor of 34 studies on the registry; 8 are open to participants now.
Royal Free Hospital NHS Foundation Trust has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
2 of the studies in Sleep Apnea, Obstructive with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07497412King's College LondonThe Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea | 2026-11 |
| NCT06030349Children's Health IrelandClinical Outcomes From Treatment and Evaluation of Obstructive Sleep Apnoea in Children With Down Syndrome | 2027-11-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obstructive sleep apnoea (OSA) is a breathing problem that happens when you sleep. It is treated by a machine called continuous positive airway pressure (CPAP) therapy.
The goal of this observational trial is to test how well a new wearable device can detect ongoing OSA in patients undergoing treatment with CPAP. The main questions it aims to answer are:
Participants will be asked to wear the following two devices while using their CPAP machine for 2 nights:
Researchers will then compare how much OSA is left in participants, comparing the values from the new device, gold standard sleep study and the CPAP machine itself.
Obstructive sleep apnoea (OSA) affects almost one billion people globally and can lead to numerous health consequences including ischaemic heart disease, hypertension, stroke and arrhythmias. It also has a profound impact on patient's quality of life and has a high economic burden on society. Continuous positive airway pressure (CPAP) therapy is globally accepted gold-standard treatment, virtually eliminating OSA (by normalising the apnoea-hypopnoea index (AHI)), thus improving quality of life, decreasing sleepiness and reducing medical sequelae. A high residual AHI may still be present despite adequate CPAP usage in some patients. This patient population will suffer with on-going / worsening somnolence, sleep apnoea symptoms and potentially increased cardiovascular risk, which will no doubt reduce their adherence thus increasing their residual AHI, perpetuating a viscous cycle.
Currently CPAP machines can store airflow and pressure data, displaying residual events and compliance indices. However, algorithms between devices vary and there are no standards on how to use the data, and there is mixed data surrounding residual event accuracy. A review by the American Thoracic Society concluded that while CPAP usage can be reliably determined from tracking systems, residual events (residual AHI) and mask leak data are not easy to interpret and differ depending on manufactures. Some studies have found that this is especially the case in relation to detecting hypopnoeic events. Therefore, a more accurate and simple system is needed to accurately determine usage and residual events, that is: standardised, reliable and independent of machine manufacturer. Overnight oximetry is used by some Trusts as a surrogate marker of residual events. However, studies that have validated overnight oximetry against polysomnography (gold standard) have found the specificity and sensitivity decrease with decreasing severity of disease. Therefore this is not a practical or reliable way to monitor patients remotely.
Therefore we aim to assess whether we can accurately measure the residual AHI with a simple, accurate, novel wearable device in patients undergoing CPAP therapy. This will enable us to accurately assess treatment effect and highlight patients who require more intensive / change in their therapy.
AcuPebble SA100 is a CE marked novel wearable device developed by Acurable Ltd which has already been validated as an automated diagnostic tool for OSA with a high positive (96%) and high negative (995) predictive value when compared to a gold standard sleep study. This is currently in clinical use. We intend to assess whether AcuPebble SA100 can also be used to accurately detect the residual AHI in patients with OSA on CPAP therapy.
Patients in this study will be asked to wear both AcuPebble SA100 and a gold standard multi-channel sleep study simultaneously, alongside using CPAP therapy for two consecutive nights. We will then compare the residual AHI from AcuPebble SA100 with gold standard, as well as comparing the accuracy of the CPAP machine AHI with gold standard. This will also enable us to detect whether AcuPebble SA100 is more accurate that the CPAP machine.
We will also assess the usability of AcuPebble SA100 in this population.
Patients with an existing diagnosis of obstructive sleep apnoea who have been established on continuous positive airway pressure (CPAP) therapy and are deemed compliant with therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This device is not being used as an interventional device but simply a monitoring tool on patients already on CPAP therapy. The device is being used within the scope of it's intended purpose as a medical device to diagnose OSA.
Accuracy of the residual AHI measured by AcuPebble SA100
Our primary outcome will be to measure the residual AHI with AcuPebble SA100 and compare the accuracy of this measurement against a gold standard multi-channel sleep study. The residual AHI is a measurement that quantifies the amount of sleep disordered breathing that is still present despite treatment.
Time frame: 6 months
Comparing the residual AHI measured by AcuPebble SA100 and the CPAP machine
To measure the residual AHI with AcuPebble SA100 and compare it to the measurement dervied from the continuous positive airway pressure (CPAP) machine. The residual AHI is a measurement that quantifies the amount of sleep disordered breathing that is still present despite treatment.
Time frame: 6 months
Accuracy of the effective AHI measured by AcuPebble SA100
To measure the total night-time AHI (effective AHI) using AcuPebble SA100 and compare this measurement to a gold standard multi-channel sleep study. The residual AHI is a measurement that quantifies the amount of sleep disordered breathing that is still present despite treatment.
Time frame: 6 months
Measure the acceptability of AcuPebble SA100
To measure how comfortable AcuPebble SA100 is to wear for people while they use their CPAP machine.
Time frame: 6 months
Plan to share: No — No plan to share individual participant data
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Feb 2024, 16 months after the start.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 16 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Free Hospital NHS Foundation Trust